← Stock Trading Canary · All insider profiles
INSIDER PROFILE · SE
Anders Ekblom
Styrelseordförande
Profile key: se|anders ekblom
Purchase history
- Companies traded
- 2
- Purchases · 12M
- 2
- Purchases · 24M
- 8
- Average purchase
- SEK 8,368,530
- Gross purchase value
- SEK 66,948,238
- Last purchase
- 2026-04-21
- Completed 20D events
- 8.0
- Outcome status
- PASS
Latest company: XSpray Pharma AB (publ)
Companies: Alligator Bioscience AB | XSpray Pharma AB (publ)
Post-purchase outcomes
Benchmark-relative outcomes are available against OMX Stockholm 30.
- Excess return = stock return − OMX Stockholm 30 return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 8Developing | 100.0% (8/8) | 25.0% (2/8) | -2.8% | -1.0% | -23.3% |
| 20D | 8Developing | 100.0% (8/8) | 12.5% (1/8) | -9.0% | -16.3% | -82.3% |
| 60D | 8Developing | 100.0% (8/8) | 12.5% (1/8) | -38.4% | -40.5% | -85.0% |
| 120D | 8Developing | 100.0% (8/8) | 12.5% (1/8) | -63.1% | -42.6% | -85.8% |
Research patterns
- First purchase in 12M
- 4/4
- Large purchase ≥ €100k
- 4/8
- Cluster buying · 15D
- 5/8
- Buying the dip · ≥20% below prior 52W high
- 8/8
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.